As shown in Fig. 2, overweight/obesity was independently associated with a poor response to neoadjuvant targeted therapy despite the patient’s age, tumor size, nodal status, hormone receptor status, Ki67 expression, or neoadjuvant targeted therapy. Here, MKI67 is linked to obesity disorder.